Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Bicalutamide (Primary) ; Degarelix (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Histrelin (Primary) ; Leuprorelin (Primary) ; Methylprednisolone (Primary) ; Nilutamide (Primary) ; Prednisone (Primary) ; Triptorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms VA STARPORT
Most Recent Events
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 19 Feb 2022 Trial design presented at the 2022 Genitourinary Cancers Symposium